File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cytotoxic therapy for severe avian influenza A (H5N1) infection

TitleCytotoxic therapy for severe avian influenza A (H5N1) infection
Authors
Issue Date2006
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet
Citation
Lancet, 2006, v. 367 n. 9513, p. 870-873 How to Cite?
AbstractThe mortality rate in documented avian influenza A virus subtype H5N1 infection is still high, which is currently reported by WHO at about 50%. Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection. There are also clinical similarities between H5N1 infection and HLH, such as massive hypercytokinaemia, cytopenia, and acute encephalitis. Importantly, patients with another severe viral infection that may be complicated by secondary HLH, severe Epstein-Barr-virus-associated HLH, have significantly better survival if specific HLH therapy (including the cytotoxic and pro-apoptotic drug etoposide) is initiated early, with survival reported to rise from about 50% to 90%. With this notable improvement in survival, specific HLH treatment, including cytotoxic therapy, could be considered in patients with severe avian influenza A infection complicated by secondary HLH.
Persistent Identifierhttp://hdl.handle.net/10722/79827
ISSN
2015 Impact Factor: 44.002
2015 SCImago Journal Rankings: 14.638
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHenter, JIen_HK
dc.contributor.authorChow, CBen_HK
dc.contributor.authorLeung, CWen_HK
dc.contributor.authorLau, YLen_HK
dc.date.accessioned2010-09-06T07:59:12Z-
dc.date.available2010-09-06T07:59:12Z-
dc.date.issued2006en_HK
dc.identifier.citationLancet, 2006, v. 367 n. 9513, p. 870-873en_HK
dc.identifier.issn0140-6736en_HK
dc.identifier.urihttp://hdl.handle.net/10722/79827-
dc.description.abstractThe mortality rate in documented avian influenza A virus subtype H5N1 infection is still high, which is currently reported by WHO at about 50%. Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection. There are also clinical similarities between H5N1 infection and HLH, such as massive hypercytokinaemia, cytopenia, and acute encephalitis. Importantly, patients with another severe viral infection that may be complicated by secondary HLH, severe Epstein-Barr-virus-associated HLH, have significantly better survival if specific HLH therapy (including the cytotoxic and pro-apoptotic drug etoposide) is initiated early, with survival reported to rise from about 50% to 90%. With this notable improvement in survival, specific HLH treatment, including cytotoxic therapy, could be considered in patients with severe avian influenza A infection complicated by secondary HLH.en_HK
dc.languageengen_HK
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lanceten_HK
dc.relation.ispartofLanceten_HK
dc.titleCytotoxic therapy for severe avian influenza A (H5N1) infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0140-6736&volume=367&issue=9513&spage=870&epage=873&date=2006&atitle=Cytotoxic+therapy+for+severe+avian+influenza+A+(H5N1)+infectionen_HK
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_HK
dc.identifier.authorityLau, YL=rp00361en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0140-6736(06)68232-9en_HK
dc.identifier.pmid16530581-
dc.identifier.scopuseid_2-s2.0-33644848507en_HK
dc.identifier.hkuros116623en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33644848507&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume367en_HK
dc.identifier.issue9513en_HK
dc.identifier.spage870en_HK
dc.identifier.epage873en_HK
dc.identifier.isiWOS:000236016500032-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.f100011543-
dc.identifier.scopusauthoridHenter, JI=7004569913en_HK
dc.identifier.scopusauthoridChow, CB=7402578582en_HK
dc.identifier.scopusauthoridLeung, CW=7402612619en_HK
dc.identifier.scopusauthoridLau, YL=7201403380en_HK
dc.identifier.citeulike920660-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats